title: Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
abstract: BACKGROUND
  Bevacizumab, a humanized recombinant anti-vascular endothelial growth factor antibody, was approved in Canada in 2010 for the treatment of high-grade glioma. We report the effectiveness and safety of bevacizumab in the treatment of patients with recurrent high-grade gliomas at a single institution.
  
  
  METHODS
  Twenty-seven consecutive patients with high-grade glioma (anaplastic glioma and glioblastoma) at first or subsequent relapse were treated with bevacizumab alone or in combination with chemotherapy. The primary endpoint was progression-free survival (PFS) and secondary endpoints were objective response rate, six month PFS, overall survival (OS), and safety profile.
  
  
  RESULTS
  The clinical benefit rate (complete and partial responses plus stable disease) was 59%. Median PFS was 4.3 (95% CI, 3.0-10.9) months, with a six month PFS rate of 43%. Median OS after current relapse was 8.9 (95% CI, 5.8-not reached) months. Ten episodes of grade 3/4 adverse events were observed in nine patients, including fatigue (n = 3), thrombocytopenia (n = 4), and myelotoxicity, febrile neutropenia, and pulmonary embolism (each n = 1).
  
  
  CONCLUSIONS
  We consider the efficacy and safety profile of bevacizumab is comparable to other cohorts of patients treated for recurrent high-grade glioma at other international institutions.
authors: Drug Development Program, Princess Margaret Hospital, Toronto, Ontario, Canada.
authors: Solmaz
authors: S
authors: Sahebjam
authors: Evgenia
authors: E
authors: Garoufalis
authors: Marie-Christine
authors: MC
authors: Guiot
authors: Thierry
authors: T
authors: Muanza
authors: Rolando
authors: R
authors: Del Maestro
authors: Kevin
authors: K
authors: Petrecca
authors: Rajesh
authors: R
authors: Sharma
authors: Petr
authors: P
authors: Kavan
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001921:Brain / Q000187:drug effects / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002170:Canada; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality; D006785:Hospitals, University; D006801:Humans; D053208:Kaplan-Meier Estimate; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab